References
- SzebeniJComplement activation-related pseudoallergy: a new class of drug-induced acute immune toxicityToxicology20052162–310612116140450
- SzebeniJComplement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicalsMol Immunol201461216317325124145
- DézsiLRosivallLHamarPSzebeniJSzénásiGRodent models of complement activation-related pseudoallergy: inducers, symptoms, inhibitors and reaction mechanismsEur J Nanomed20157115
- ProctorLMMooreTAMonkPNSandersonSDTaylorSMWoodruffTMComplement factors C3a and C5a have distinct hemodynamic effects in the ratInt Immunopharmacol20099680080619285573
- EngströmGHedbladBBerglundGJanzonLLindgärdeFPlasma levels of complement C3 is associated with development of hypertension: a longitudinal cohort studyJ Hum Hypertens200721427628217167524
- NgTTDenningDWLiposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use dataArch Intern Med199515510109310987748054
- SchneiderPKleinRMDietzeLSöhngenDLeschkeMHeyllAAnaphylactic reaction to liposomal amphotericin (AmBisome)Br J Haematol19981024110811099734666
- BorroJMSoléAde La TorreMEfficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantationTransplant Proc20084093090309319010204
- CookGFranklinIMAdverse drug reactions associated with the administration of amphotericin B lipid complex (Abelcet)Bone Marrow Transplant199923121325132610414925
- FurebringMÖbergGSjölinJSide-effects of amphotericin B lipid complex (Abelcet) in the Scandinavian populationBone Marrow Transplant200025334134210673711
- Chanan-KhanASzebeniJSavaySComplement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactionsAnn Oncol20031491430143712954584
- Kozma GergelyTMészárosTWeiszhárZVariable association of complement activation by rituximab and paclitaxel in cancer patients in vivo and in their screening serum in vitro with clinical manifestations of hypersensitivity: a pilot studyEur J Nanomed20157289
- SzebeniJFontanaJLWassefNMHemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibodyCirculation199999172302230910226097
- SzebeniJBaranyiLSavaySLiposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reactionAm J Physiol Heart Circ Physiol20002793H1319H132810993799
- SzebeniJBaranyiLSávaySComplement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart functionAm J Physiol Heart Circ Physiol20062903H1050H105816214844
- SzebeniJBedőcsPCsukásDRosivallLBüngerRUrbanicsRA porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicinesAdv Drug Deliv Rev201264151706171622820530
- SzebeniJBedőcsPUrbanicsRPrevention of infusion reactions to pegylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine modelJ Control Release2012160238238722421426
- UrbanicsRBedőcsPSzebeniJLessons learned from the porcine CARPA model: constant and variable responses to different nanomedicines and administration protocolsEur J Nanomed201573219
- JackmanJAMészárosTFülöpTUrbanicsRSzebeniJChoNJComparison of complement activation-related pseudoallergy in miniature and domestic pigs: Foundation of a validatable immune toxicity modelNanomedicine201612493394326767512
- DézsiLFülöpTMészárosTFeatures of complement activation-related pseudoallergy to liposomes with different surface charge and pegylation: comparison of the porcine and rat responsesJ Control Release201419521025148822
- Adler-MooreJPProffittRTDevelopment, characterization, efficacy and mode of action of ambisome, a unilamellar liposomal formulation of amphotericin BJ Liposome Res199333429450
- JanoffASBoniLTPopescuMCUnusual lipid structures selectively reduce the toxicity of amphotericin BProc Natl Acad Sci U S A19888516612261263413081
- BaranyiLSzebeniJSávaySComplement-dependent shock and tissue damage induced by intravenous injection of cholesterol-enriched liposomes in ratsJ Appl Res200333221231
- CedroneENeunBRodriguezJAnticoagulants influence the performance of in vitro assays intended for characterization of nanotechnology-based formulationsMolecules201723112
- MollnesTEBrekkeOLFungMEssential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammationBlood200210051869187712176911
- CatellaFHealyDLawsonJAFitzgeraldGA11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulationProc Natl Acad Sci U S A19868316586158653461463
- MarceauFLundbergCHugliTEEffects of the anaphylatoxins on circulationImmunopharmacology198714267842828271
- MészárosTKozmaGTShimizuTInvolvement of complement activation in the pulmonary vasoactivity of polystyrene nanoparticles in pigs: unique surface properties underlying alternative pathway activation and instant opsonizationInt J Nanomedicine2018136345635730349254
- SzebeniJBedőcsPRozsnyayZLiposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisomeNanomedicine20128217618421704590
- SzebeniJSimbergDGonzález-FernándezÁBarenholzYDobrovolskaiaMARoadmap and strategy for overcoming infusion reactions to nanomedicinesNat Nanotechnol201813121100110830348955
- RingdénOJønssonVHansenMTollemarJJacobsenNSevere and common side-effects of amphotericin B lipid complex (Abelcet)Bone Marrow Transplant19982277337349818706
- NorisMRemuzziGOverview of complement activation and regulationSemin Nephrol20133347949224161035